Reaction
Bacillus Infection reporting signals
As of the last recalculation, Bacillus Infection appears in 617 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is TOFACITINIB CITRATE (PRR 72.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tofacitinib Citrate | 27 | 72.6 | 72.8 |
| Mercaptopurine | 33 | 67.8 | 67.9 |
| Azacitidine For | 33 | 64.6 | 64.7 |
| Gentamicin | 22 | 58.8 | 58.9 |
| Raltegravir | 26 | 55.4 | 55.5 |
| Gentamicin Sulfate | 23 | 51.0 | 51.0 |
| Pegaspargase | 17 | 48.1 | 48.2 |
| Desoximetasone | 25 | 46.1 | 46.2 |
| Cytarabine | 71 | 44.9 | 45.0 |
| Obinutuzumab | 21 | 44.5 | 44.6 |
| Azacitidine | 35 | 42.1 | 42.2 |
| Ampicillin | 10 | 41.4 | 41.4 |
| Ampicillin Sodium | 10 | 41.4 | 41.4 |
| Micafungin Sodium | 9 | 36.3 | 36.4 |
| Cefepime | 13 | 31.2 | 31.3 |
| Mycophenilic Acid | 17 | 28.4 | 28.5 |
| Cefepime Hydrochloride | 13 | 27.8 | 27.8 |
| Vincristine Sulfate | 23 | 27.5 | 27.5 |
| Moxifloxacin | 11 | 26.8 | 26.8 |
| Amphotericin B | 9 | 24.6 | 24.6 |
| Filgrastim | 25 | 23.3 | 23.3 |
| Meropenem | 21 | 22.8 | 22.8 |
| Vancomycin | 35 | 21.6 | 21.6 |
| Venetoclax | 36 | 20.9 | 20.9 |
| Piperacillin Sodium,Tazobactam Sodium | 16 | 20.9 | 20.9 |
| Fludarabine Phosphate | 23 | 20.5 | 20.5 |
| Sirolimus | 8 | 20.3 | 20.3 |
| Rifampicin | 6 | 20.2 | 20.2 |
| Busulfan | 9 | 19.6 | 19.6 |
| Durvalumab | 11 | 18.6 | 18.6 |
| Thiotepa | 5 | 17.8 | 17.8 |
| Mesna Injection | 4 | 16.4 | 16.4 |
| Mesna | 4 | 16.1 | 16.1 |
| Emtricitabine And Tenofovir Disoproxil Fumarate | 17 | 12.9 | 12.9 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 5 | 5.5 | 5.5 |